Humana Inc. $HUM Shares Bought by Banque Pictet & Cie SA

Key Points

• Banque Pictet & Cie SA increased its stake in Humana Inc. by 9.9%, owning a total of 44,719 shares valued at approximately $10.93 million after purchasing an additional 4,024 shares.
• Humana reported earnings per share (EPS) of $6.27 for the quarter, which was below the consensus estimate of $6.32, despite a 9.6% year-over-year revenue increase reaching $32.39 billion.
• The company has announced a quarterly dividend of $0.885 per share, with the ex-dividend date set for September 26th, reflecting a dividend yield of 1.4%.

Banque Pictet & Cie SA boosted its stake in Humana Inc. (NYSE:HUM - Free Report) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,719 shares of the insurance provider's stock after buying an additional 4,024 shares during the period. Banque Pictet & Cie SA's holdings in Humana were worth $10,933,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in HUM. Janney Montgomery Scott LLC acquired a new stake in shares of Humana in the 1st quarter worth approximately $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Humana by 16.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider's stock worth $300,728,000 after purchasing an additional 158,528 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Humana by 104.2% in the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider's stock valued at $1,701,000 after purchasing an additional 3,281 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after acquiring an additional 2,950 shares in the last quarter. Finally, Circle Wealth Management LLC purchased a new position in Humana during the 1st quarter valued at about $425,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

HUM opened at $254.35 on Friday. The firm has a market cap of $30.59 billion, a PE ratio of 19.52, a P/E/G ratio of 1.54 and a beta of 0.44. The stock has a 50-day moving average price of $271.22 and a 200-day moving average price of $257.28. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $324.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the prior year, the company posted $6.96 EPS. The company's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. Humana's payout ratio is 27.17%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research reports. Morgan Stanley decreased their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Evercore ISI initiated coverage on Humana in a research note on Monday. They issued an "in-line" rating and a $295.00 price target for the company. Royal Bank Of Canada increased their price objective on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Sanford C. Bernstein raised their target price on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Finally, Robert W. Baird lowered their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Seven analysts have rated the stock with a Buy rating and seventeen have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $289.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.